Cours Invictus MD Strategies Corp Toronto S.E.
Actions
GENE
CA46183X2086
Produits pharmaceutiques
Cours en clôture
Autres places de cotation
|
||
- CAD | - |
|
CA 2018 | 2,36 3,22 2,11 | CA 2019 | 4,69 6,39 4,2 | Capitalisation | 104 M 141 M 92,55 M |
---|---|---|---|---|---|
Résultat net 2018 | -19 M -25,88 M -16,99 M | Résultat net 2019 | -35 M -47,67 M -31,29 M | VE / CA 2018 | 45 833 024 x |
Trésorerie nette 2018 | 37,59 M 51,21 M 33,61 M | Dette nette 2019 | 3,85 M 5,24 M 3,44 M | VE / CA 2019 | 22 877 117 x |
PER 2018 |
-5,87
x | PER 2019 |
-2,45
x | Employés | - |
Rendement 2018 * |
-
| Rendement 2019 |
-
| Flottant | 6,83% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Imran Haider
CEO | Chief Executive Officer | - | - |
Trevor Dixon
BRD | Director/Board Member | - | 09/05/19 |
Larry Heinzlmeir
IRO | Public Communications Contact | - | 24/01/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Trevor Dixon
BRD | Director/Board Member | - | 09/05/19 |
Jagdeep Gupta
BRD | Director/Board Member | - | 22/02/22 |
Greg Macdonald
BRD | Director/Board Member | - | 26/01/21 |
Varia. 1 janv. | Capi. | |
---|---|---|
+17,11% | 5,11 Md | |
-35,20% | 3,43 Md | |
-2,64% | 3,05 Md | |
-25,79% | 2,59 Md | |
-14,23% | 2,2 Md | |
+40,50% | 1,86 Md | |
+41,90% | 1,38 Md | |
-16,36% | 1,37 Md | |
+32,83% | 1,36 Md |
- Bourse
- Actions
- Action IVITF
- Action GENE